Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.

NCT00258557 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00258557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
May 31, 2012
Enrollment
692 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

hiv